107 related articles for article (PubMed ID: 12962370)
1. CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.
Lim WT; Lim ST; Wong NS; Koo WH
J Chemother; 2003 Aug; 15(4):400-5. PubMed ID: 12962370
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Oncology (Williston Park); 2002 May; 16(5 Suppl 5):16-8. PubMed ID: 12109800
[TBL] [Abstract][Full Text] [Related]
3. Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
Shimoyama S; Aoki F; Shimizu N; Tatsutomi Y; Mafune K; Kaminishi M
Int J Clin Oncol; 2003 Feb; 8(1):49-52. PubMed ID: 12601543
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
Nagahori Y; Nagahori K; Hamaguchi Y; Fukushima T; Masui H; Mogaki M; Abe T
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1555-9. PubMed ID: 18799911
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
Newman E; Marcus SG; Potmesil M; Sewak S; Yee H; Sorich J; Hayek M; Muggia F; Hochster H
J Gastrointest Surg; 2002; 6(2):212-23; discussion 223. PubMed ID: 11992807
[TBL] [Abstract][Full Text] [Related]
6. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma.
Ajani JA; Lee FC; Singh DA; Haller DG; Lenz HJ; Benson AB; Yanagihara R; Phan AT; Yao JC; Strumberg D
J Clin Oncol; 2006 Feb; 24(4):663-7. PubMed ID: 16446338
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
[TBL] [Abstract][Full Text] [Related]
9. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
[TBL] [Abstract][Full Text] [Related]
12. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Ajani JA; Baker J; Pisters PW; Ho L; Mansfield PF; Feig BW; Charnsangavej C
Cancer; 2002 Feb; 94(3):641-6. PubMed ID: 11857295
[TBL] [Abstract][Full Text] [Related]
13. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Shirao K; Shimada Y; Kondo H; Saito D; Yamao T; Ono H; Yokoyama T; Fukuda H; Oka M; Watanabe Y; Ohtsu A; Boku N; Fujii T; Oda Y; Muro K; Yoshida S
J Clin Oncol; 1997 Mar; 15(3):921-7. PubMed ID: 9060529
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Rivera F; Galán M; Tabernero J; Cervantes A; Vega-Villegas ME; Gallego J; Laquente B; Rodríguez E; Carrato A; Escudero P; Massutí B; Alonso-Orduña V; Cardenal A; Sáenz A; Giralt J; Yuste AL; Antón A; Aranda E;
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1430-6. PubMed ID: 19540072
[TBL] [Abstract][Full Text] [Related]
15. Phase 1/11 study of bi-weekly irinotecan plus cisplatin in the treatment of advanced gastric cancer.
Koizumi W; Kurihara M; Satoh A; Takiuchi H; Tanabe S; Shimada K; Iwasaki R; Saigenji K
Anticancer Res; 2005; 25(2B):1257-62. PubMed ID: 15865075
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy of low-dose CDDP and CPT-11 therapy as second- or third-line chemotherapy for advanced and recurrent gastric cancer].
Ito S; Takagawa R; Minami Y; Watanabe J; Morita T; Mogaki M; Masui H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1107-11. PubMed ID: 25248893
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of irinotecan in combination with cisplatin as second-line chemotherapy in patients with metastatic or locally advanced gastric cancer.
Shen WC; Yang TS; Hsu HC; Chen JS
Chang Gung Med J; 2011; 34(6):590-8. PubMed ID: 22196061
[TBL] [Abstract][Full Text] [Related]
18. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
19. [Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer].
Godai TI; Oshima T; Numata M; Fukahori M; Sato T; Makino H; Fujii S; Rino Y; Masuda M; Imada T; Kunisaki C
Gan To Kagaku Ryoho; 2011 Jun; 38(6):945-9. PubMed ID: 21677484
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR
Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
